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Summary
 
The transporter associated with antigen presentation (TAP) complex shuttles cytosolic peptides
into the exocytic compartment for association with nascent major histocompatibility complex
class I molecules. Biochemical studies of murine and human TAP have established that sub-
strate length and COOH-terminal residue identity are strong determinants of transport effi-
ciency. However, the existence of these specificities in the intact cell and their influences on T
cell responses have not been demonstrated. We have devised a method for studying TAP-
mediated transport in intact cells, using T cell activation as a readout. The approach makes use
 
of a panel of recombinant vaccinia viruses expressing peptides containing the K
 
d
 
-restricted
nonamer influenza nucleoprotein residues 147–155. The COOH terminus of each construct
was appended with a dipeptide composed of an internal threonine residue followed by a vary-
ing amino acid. Synthetic peptide versions of these 11-mers exhibit vastly different transport
capabilities in streptolysin O–permeabilized cells, in accordance with the predicted influence of
the COOH-terminal residues. Presentation of the endogenously expressed version of each
construct requires TAP-mediated transport and cooexpression with a vac-encoded exocytic
COOH-terminal dipeptidase, angiotensin converting enzyme, to allow liberation of the mini-
mal epitope. Recognition by epitope-specific CTLs therefore signifies TAP-mediated transport
of a complete 11-mer within the target cell. Under normal assay conditions no influences of
the COOH-terminal residue were revealed. However, when T cell recognition was limited,
either by blocking CD8 coreceptor interactions or by decreasing the amount of transport sub-
strate synthesized, significant COOH-terminal effects were revealed. Under such conditions,
those peptides that transported poorly in biochemical assays were less efficiently presented.
Therefore, TAP specificity operates in the intact cell, appears to reflect previously defined rules
with regard to the influence of the COOH-terminal residue, and can strongly influence T cell
responses.
 
C
 
D8
 
1
 
 CTLs recognize short (8–10-amino acid) peptide
portions of antigen (epitopes) complexed with major
histocompatibility class I molecules (1–3). The initial pro-
cessing of most antigens destined for recognition by class
I–restricted CTLs occurs in the cytosol. The resultant frag-
ments are then conveyed to the exocytic compartment by
the transporter associated with antigen presentation (TAP)
 
1
 
heterodimer where, perhaps after further processing, they
become available for binding to nascent class I. Because of
this function, the TAP complex, a member of the ABC
family of transporters (4, 5), is critical for presentation of
 
the vast majority of class I–restricted epitopes, as well as for
the surface expression of class I molecules themselves (6).
Numerous potential epitopes are contained within an
antigenic protein, but very few trigger CTL responses. Al-
though much of this selectivity can be attributed to strin-
gent haplotype-specific class I binding requirements (7),
other factors determining epitope immunogenicity include
the availability of appropriate T cell specificities and the
ability of the proteolytic machinery to excise the epitope
without destroying it too rapidly (8, 9). As understanding
of the critical role of TAP in class I–restricted antigen pre-
sentation has grown, it has been intriguing to speculate that
TAP substrate specificity may also have a significant hand
in determining which epitopes are available for T cell rec-
ognition.
It was initially observed that polymorphism at the rat 
 
cim
 
1
 
Abbreviations used in this paper:
 
 ACE, angiotensin converting enzyme;
IC
 
50
 
, 50% inhibitory concentration; NP, influenza nucleoprotein; TAP,
transporter associated with antigen presentation; TE, 147–155TE; TG,
147–155TG; TL, 147–155TL; TM, 147–155TM; TP, 147–155TP; TX,
147–155TX; vac, vaccinia.
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locus, the TAP homologue in that species, could be corre-
lated with variability in the array of class I–associated pep-
tides (10). This finding was of particular significance be-
cause it implied an influence of transport specificity in a
relatively unmanipulated system. Although the 
 
cim
 
 effect
could be shown to influence T cell responses in the rat, it is
important to note that the 
 
cim
 
 locus exhibits far greater
variability than does the TAP locus in either mice or hu-
mans (3). This approach, applied to a study of class I–asso-
ciated peptides in mice and humans, has failed to identify a
similar influence of allelic variation on TAP specificity (11,
12). However, in vitro biochemical assays, using either
streptolysin O–permeabilized cells or isolated microsomes,
have provided evidence for substrate preferences by all
TAP alleles in both species (13–18). By these means, a size
optimum of 8–12 residues has been established, and it has
been found that mouse TAPs prefer peptides with hydro-
phobic COOH-terminal residues; human TAPs transport
peptides with both hydrophobic and acidic COOH termini
(19, 20). These preferences are consistent with MHC bind-
ing capabilities and this, along with the genetic linkage be-
tween TAP and MHC (3), has given rise to the speculation
that the two have coevolved to enhance the efficiency of
the class I–restricted response. To date, these biochemical
assays provide the only evidence for murine or human
TAP selectivity; as yet it is undemonstrated whether the
measured preferences have significance for T cell recognition.
Some evidence suggests that murine TAP specificity may
not play a large role in shaping T cell responses. It is clear
that substrates showing little or no transport capability in in
vitro transport assays can be presented to T cells and serve
as potent immunogens in vivo. Shepherd et al. previously
reported that the minimal epitope influenza nucleoprotein
residues 147–155 (NP
 
147–155
 
) is not detectably transported
into isolated microsomes, with a 50% inhibitory concentra-
tion (IC
 
50
 
) value of 
 
.
 
50 
 
m
 
M (14). Although these authors
suggested that a longer fragment containing the epitope
may be transported and further processed in the exocytic
compartment, a minigene expressing only the minimal
epitope is a more efficient immunogen than full-length NP
(21, 22). Furthermore, it has been reported that cells ex-
pressing murine TAP and the human HLA-A3 gene prod-
uct can efficiently produce ligands for this class I molecule
despite its preference for positively charged COOH ter-
mini (23), which are likely to be generated before transport
(24). Given the high sensitivity of T cells, it is possible that
TAP selectivity may not significantly impact their responses
under physiological conditions. Additionally, as with in vitro
nuclear transport assays (25), streptolysin O and microsome
isolation may lead to a loss of molecules that influence
transport in vivo. It is possible that such molecules physi-
cally interact with the TAP complex, processed fragments,
or both, to influence transport specificity and/or rates.
Therefore, we wished to test whether biochemically estab-
lished transport capability was in fact correlated with TAP
selectivity within intact cells and, if so, begin to elucidate
conditions of antigen expression and CTL sensitivity under
which selectivity might influence an immune response.
 
In this study, we describe a unique approach to measur-
ing the influence of TAP specificity within live, intact cells,
using the physiologically significant readout of CTL recog-
nition. A previous study demonstrated that the K
 
d
 
-restricted
influenza nucleoprotein epitope, amino acids 147–155,
cannot be processed and presented when appended by two
COOH-terminal residues, threonine and glycine, due to
the unavailability of appropriate proteolytic activity (21).
Presentation of the epitope can take place when the frag-
ment is coexpressed with the dipeptidyl carboxypeptidase
angiotensin converting enzyme (ACE; references 26 and
27). As rescue is intracellular and TAP-dependent, and this
enzyme is active only in the exocytic compartment, and ACE-
mediated processing of the 11-mer is a reflection of TAP-
mediated transport within intact target cells (see Fig. 1 for a
schematic of this process). We have used this system to ex-
amine class I–restricted presentation of an array of substrates
that differ significantly in their in vitro transport capabilities.
 
Materials and Methods
 
Cell Lines.
 
The L-K
 
d
 
 (L929 transfected with the K
 
d
 
 gene) cell
line was maintained in DMEM, 5% FCS. RMA and RMA-S
cells were maintained in RPMI, 5% FCS.
 
Peptides and Antibodies.
 
Peptides were acquired from Research
Genetics (Huntsville, AL) and either were obtained at 
 
.
 
90% pu-
rity or were purified by reverse-phase HPLC. Purified anti-CD8
 
b
 
 subunit antibody 2.43 was provided by Dr. Y. Sykulev (Jeffer-
son Medical College).
 
PCR-based Mutagenesis and Vaccinia Virus Generation.
 
Minigenes
and minigene-encoding vaccinia (vac) recombinants were generated
as previously described (21) with the following modification: mini-
genes were made by PCR of the 
 
NP/R
 
2
 
 gene. The synthetic oligo-
nucleotide primers used contained a SalI site in the upstream primer
and a NotI site in the downstream primer to enable directional li-
gation. The downstream primer contained random bases at the
triplet encoding the residue at the “X” position. All minigenes
were preceded by Kozak’s consensus sequence and an initiating
methionine and followed by two stop codons to ensure efficient
and accurate translation (28). After ligation into a modified
pSC11 plasmid, DNA was isolated from random colonies and se-
quenced to determine the identity of the randomly mutated resi-
due. ACE vac has been previously described (27). Cytosolic ACE
was generated by PCR of the ACE gene. The synthetic oligonu-
cleotide primers used contained a NotI site in the upstream
primer and XhoI in the downstream primer to anneal to a unique
XhoI site within ACE. The upstream primer annealed to the por-
tion of ACE directly after the leader sequence. The PCR product
was cloned into NotI-XhoI cut pBS-KS
 
1
 
-ACE and then shuttled
into the modified pSC11 for recombination into vac. Radioim-
Figure 1. Schematic diagram
of transport-dependent ACE-
mediated processing in the exo-
cytic compartment. 
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munoprecipitation of cytosolic ACE vac-infected cells yielded
two rapidly degraded anti-ACE–specific bands as previously ob-
served (27). Generation of the pSC11 plasmid containing the
original thermostable duplex barrier (HP20) construct has been
previously described (29) and contained a KpnI site at the top of
the hairpin loop structure. To generate constructs with two
(HP18), four (HP16), or six (HP14) mismatched bps, synthetic
oligonucleotide pairs encoding the desired changes and designed
to ablate the KpnI site after successful ligation were inserted into
KpnI-SalI cut vector. SalI/NotI-ended 147–155TX (TX) con-
structs were ligated into these vectors and the resulting plasmids
were used to generate vac recombinants.
 
Target Cell Sensitization by Vaccinia Virus Infection.
 
L-K
 
d
 
 cells (L929
cells stably expressing the class I K
 
d
 
 molecule at the cell surface)
were trypsinized, washed once with balanced salt solution with
0.1% BSA (BSS/BSA), placed at 2 
 
3
 
 10
 
7
 
 cells/ml in BSS/BSA,
and infected for 1 h with 5 PFU/cell vac. Cells were then diluted
with Iscove’s medium and infection proceeded for an additional 3 h.
 
CTL Assays.
 
CTL assays were performed as described else-
where (21). Infected cells were pelleted, suspended at 4 
 
3
 
 10
 
7
 
cells/ml in Iscove’s medium with 100 
 
m
 
Ci 
 
51
 
Cr, and incubated
for 1 h at 37
 
8
 
C. Cells were then washed three times with PBS,
suspended in medium, and combined with NP-specific CTLs.
Targets and CTLs were coincubated for 4 h at 37
 
8
 
C, then super-
natants were collected and counted. For assays using the partially
blocking anti-CD8 antibodies, CTLs, used at a constant effector/
target ratio of 10:1, were coincubated with the antibody dilutions
for 30 min before addition of the chromium-labeled target cells.
 
Generation of CTL.
 
CTL populations were generated as pre-
viously described (21). BALB/c mice (H-2
 
d
 
 haplotype) were in-
jected intraperitoneally with 10
 
7
 
 PFU of vac recombinants ex-
pressing NP
 
M147–155
 
. After at least 2 wk, splenocytes were
harvested. One-third of total spleen cells was infected with PR8,
washed, and then mixed with the remaining cells in Iscove’s me-
dium. Cultures were harvested after 6 or 7 d and used in CTL assays.
 
Streptolysin O Peptide Transport Assay.
 
In vitro assay of TAP-
mediated peptide transport was performed as previously described
(17). RMA cells (3 
 
3
 
 10
 
6
 
/sample) were permeabilized with
streptolysin O (2 U/ml; Murex Diagnostics, Norcross, GA) and
incubated for 15 min at 37
 
8
 
C with 
 
z
 
100 ng radioiodinated re-
porter peptide (amino acid sequence TVNKTERAY, described
in reference 17, iodinated by the Enzymobead method, Bio-Rad,
Hercules, CA, to a specific activity of 
 
z
 
20 
 
m
 
Ci/
 
m
 
g), 10 
 
m
 
l 100
mM ATP, and indicated dilutions of competitor peptides. Glyco-
sylated reporter peptide (indicating transport to the exocytic
compartment) was recovered using Con A Sepharose (Pharmacia,
Biotech AB, Uppsala, Sweden) and quantitated on a gamma
counter. The peptides were tested without the initiating me-
thionine due to the predicted action of methionyl aminopeptidase
on the endogenously expressed substrates. Reporter peptide
transport in TAP-minus RMA-S cells was always assessed as a
negative control and typically yielded counts 
 
,
 
2% of those seen
with RMA 
 
1
 
 reporter peptide alone. Samples were done singly
except for RMA cells with no competitor, which was done in
duplicate. The experiment was repeated four times, and each
time yielded similar results.
 
Measurement of the Kinetics of ACE-mediated Substrate Modifica-
tion.
 
10 ng of synthetic peptide was coincubated with ACE
(0.001 U; Sigma Chemical Co., St. Louis, MO) in Hepes-buff-
ered saline, pH 7.3, in a 20-
 
m
 
l reaction. At the indicated time
points, samples were frozen on ethanol/dry ice, and then dried
and analyzed by reverse-phase HPLC. Reactions were monitored
by the disappearance of a peak corresponding to starting substrate.
Substrate concentrations at the various time points were calcu-
lated based on the peak area of 10 nM of starting substrate. Ini-
tially both reactions resulted in the appearance, at comparable ki-
netics, of a species which coeluted with synthetic 147–155. This
species was eventually also destroyed by ACE.
 
Radioimmunoprecipitation.
 
10
 
6
 
 L-K
 
d
 
 were infected for 1 h with
10 PFU/cell of the indicated vacs in BSS/BSA, followed by the
addition of 1 ml of methionine-free DME containing 70 
 
m
 
Ci
[
 
35
 
S]methionine (Amersham Corp., Arlington Heights, IL). In-
fection proceeded for an additional 5 h and then cells were lysed
in 140 mM NaCl, 10 mM Tris, pH 7.4, 0.5% NP-40, and 2 mM
PMSF. Nuclei were removed at high speed centrifugation, lysates
were precleared with protein A–Sepharose beads overnight, and
were then incubated for 90 min with protein A–Sepharose beads
coupled with the NP-specific antibodies HB65 and H19-S24
(provided by Dr. W. Gerhard, Wistar Institute, Philadelphia, PA).
Washed pellets were boiled in reducing SDS-PAGE sample
buffer, then 10-fold dilutions were made of the supernatant from
the wild-type NP sample for comparison to undiluted superna-
tants from the HP vacs. Samples were analyzed on an SDS-PAGE
10% gel. Relative band intensities were determined by scanning
the gel with a Personal Densitometer SI (Molecular Dynamics,
Sunnyvale, CA) using a Windows workstation.
 
Results
 
ACE-mediated Rescue of a Panel of 11-mer Fragments.
 
A panel
of vacs was generated containing an array of TX minigenes
in which the residue at the COOH-terminal position was
randomly changed. Eight constructs were made, with sub-
stitutions representing each of the amino acid types and,
more importantly, representing examples of COOH-ter-
minal residues previously shown to have either a positive or
negative influence on transport (15, 17). All of the con-
structs studied contain an initiating methionine that is pre-
dicted to be removed by methionyl aminopeptidase (30),
and which has therefore been eliminated from the nomen-
clature.
None of these constructs was presented in the absence of
ACE, reiterating severe limitations on available mono- or
dipeptidyl carboxypeptidase activity suggested by the TG
block of presentation (Fig. 2). When coexpressed with
ACE, every TX vac sensitized target cells for lysis by
NP-specific CTLs. One trivial explanation for this phe-
nomenon is that the COOH-terminal (X) residue may be
cleaved in the cytosol, followed by transport and uncon-
ventional ACE-mediated removal of the remaining threo-
nine. To address this possibility, we generated and tested a
vac recombinant that expressed 147–155T (with no X resi-
due). This construct failed to sensitize target cells for NP-
specific lysis above background levels, and its presentation
could not be rescued by ACE. Also shown in this figure, a
form of ACE intentionally delivered to the cytosol failed to
process TG and all other TX constructs tested. Taken with
the previous finding that cytosolically delivered ACE is
rapidly degraded and all detectable intracellular wild-type
ACE activity segregates with the glycosylated form of the
enzyme (27), this result indicates that the effects seen in our
system are not due to anomalous expression of small
amounts of ACE within the cytosol, and is consistent with 
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a strict requirement for transport to the exocytic compart-
ment. Thus, each member of the panel is transported suffi-
ciently well within an intact cell to stimulate recognition
and lysis by class I–restricted CTLs in an optimized chro-
mium release assay.
 
In Vitro Transport of TX Mutant Constructs.
 
Because each
construct sensitized target cells for recognition by CTLs,
we considered the possibility that these substrates do not
differ in their transport capabilities despite the predicted in-
fluence of the COOH-terminal replacements (15, 17).
Synthetic versions of selected constructs predicted to be ei-
ther transport-permissive (147–155TL, –TM) or -nonper-
missive (147–155TP, –TE, –TG) were tested for their abil-
ity to inhibit TAP-dependent transport of the radiolabeled
reporter peptide, TVNKTERAY (17), in streptolysin O–per-
meabilized RMA cells (Fig. 3). TL and TM were both well-
transported, with IC
 
50
 
 values of 
 
z
 
10 
 
m
 
M. TP was transported
at a rate at least a log below that of the well-transported sub-
strates, with inhibition of reporter peptide transport occur-
ring only at substrate concentrations well above those nor-
mally tested in this type of assay. Unexpectedly, we frequently
observed an enhancement rather than inhibition of reporter
peptide transport in the presence of both TE and TG. We
are presently investigating this intriguing phenomenon, but
based on this data can only state that neither of these sub-
strates appears to be transported under the conditions of
this assay. This property was also exhibited by the unap-
pended minimal epitope, generally in agreement with a
previously reported IC
 
50
 
 value of 
 
.
 
50 
 
m
 
M (14). Therefore,
this panel of substrates exhibits a wide range of in vitro trans-
port capabilities. Note that, although rules regarding the
influence of COOH-terminal residues on transport have
been established on a limited range of test peptides, predic-
tions of transport capability based on these rules were com-
pletely borne out.
 
Purified ACE-mediated Modification of the Synthetic Form of
Each TX Construct.
 
It was necessary to ensure that differ-
ences in ACE-mediated substrate modification would not
confound our analysis, perhaps masking true transport dif-
ferences. Purified ACE was incubated with a starting con-
centration of 10 nM of synthetic peptide. The reaction was
stopped at various time points and the reaction products
were analyzed by reverse-phase HPLC. The kinetics of
ACE-mediated peptide modification were determined by
following the rate of disappearance of the peak representing
starting substrate (Fig. 4). Of the substrates tested, only
ACE-mediated presentation of TE differed significantly from
the other substrates, being modified more slowly. There-
fore, this construct was excluded from further analysis. Con-
sistent with this, note that this construct exhibited slightly
but repeatably lower levels of presentation under standard
assay conditions (Fig. 2).
 
Comparison of Presentation Efficiencies under Suboptimal Con-
ditions.
 
It has been demonstrated that, under the conditions
of vaccinia-driven antigen expression and the time course
of the typical chromium release assays, it can be difficult to
resolve significant differences in presentation efficiencies (9,
31). For example, if only 15 MHC–peptide complexes are
required on the cell surface to stimulate optimal levels of T
cell lysis, then any processing events that yield more than
this relatively small number will stimulate similar lysis lev-
els. To ensure the finest resolution, the assay must be per-
formed under conditions that are suboptimal for T cell rec-
ognition. This may be accomplished by limiting the number
of MHC–peptide complexes that reach the cell surface
through the addition of the fungal metabolite brefeldin A
(32–34), by limiting T cell receptor–ligand interaction
through the use of partially blocking anti–T cell receptor or
anti-CD8 antibodies, or by limiting the amount of starting
substrate through genetic manipulations of the test con-
structs.
 
Partial T Cell Receptor Blocking with Anti-CD8 Antibod-
ies.
 
When we examined presentation of the epitope from
the various TX contexts following the addition of brefeldin
A at numerous time points after infection, we failed to dis-
tinguish presentation differences between them (data not
Figure 2. A panel of 147–155TX minigene-expressing vac recombi-
nants containing random amino acid replacements at the COOH-termi-
nal X position are all transported, processed by ACE, and presented by in-
tact target cells. L-Kd cells were infected for 4 h with 5 PFU of the
indicated vac with 5 PFU of control virus (open bars), or with 5 PFU ACE
vac (solid bars), or cytosolically delivered ACE vac (hatched bars). 51Cr-labeled
target cells were then assessed for recognition by NP147–155-specific CTL
at an effector/target ratio of 50:1. Control virus in these experiments was
NP296–498 vac.
Figure 3. In vitro transport of synthetic versions of the 147-155TX
constructs. RMA cells were permeabilized with streptolysin O (2 U/ml)
and incubated with radioiodinated reporter peptide (amino acid sequence
TVNKTERAY) plus the indicated dilutions of test peptides. Reporter
peptide transport in TAP-minus RMA-S cells was always assessed as a
negative control and typically yielded counts ,2% of those seen with
RMA 1 reporter peptide alone. Samples were done singly except for
RMA cells with no competitor, done in duplicate. The experiment was
repeated four times, all yielding similar results. 
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shown). However, the two other approaches described
above yielded more discriminating results. First, we exam-
ined ACE-mediated presentation of the constructs in the
presence of increasing doses of purified 2.43, a monoclonal
antibody directed to the 
 
b
 
 subunit of CD8. Although the
results were somewhat variable between experiments, this
antibody will completely block CTL recognition at doses
of 5–10 
 
m
 
g/ml. As shown in Fig. 5, susceptibility to the
blocking antibodies across the panel of constructs precisely
mirrored the in vitro transport capability of the peptides.
Presentation of TG, which exhibited no detectable trans-
port in streptolysin O–permeabilized cells, was severely in-
hibited at 1 
 
m
 
g/ml of the antibody. This concentration had
a lesser, but still significant, blocking effect on TP presenta-
tion, a poorly transported substrate. The very well trans-
ported substrates, TL and TM, showed only slightly subopti-
mal presentation levels under this condition. This pattern
of differential susceptibility was maintained at decreasing
antibody doses. Even at a concentration of 0.1 
 
m
 
g/ml, per-
haps one-tenth the concentration of antibody required to
block optimally expressed peptide complexes, the poorly
transported TG suboptimally sensitized target cells for lysis.
Therefore, under conditions of limited T cell stimulation,
biochemically established rules of transport capability also
appear to apply within the intact cell.
 
Limiting Starting Levels of Antigen Expression.
 
It is possi-
ble that levels of antigen expression resulting from in vitro
vac infection of target cells are higher than those that occur
in many physiological situations. This is particularly a con-
cern with minigene products (31). We therefore wished to
assess presentation when starting substrate expression was
limited. To do this, we made use of a previously described
thermostable duplex barrier, comprised of a hairpin struc-
ture containing 20 paired bases (HP20; reference 29).
When placed between the P7.5 vac promoter and the initi-
ating methionine of the vac-encoded NP, presentation of
three NP epitopes was significantly reduced (29). We ex-
tended this approach to include three additional structures,
denoted HP18, HP16, and HP14, each containing two,
four, or six fewer base pairings than the original structure.
This panel was used to try to ensure that we would achieve
suboptimal conditions for each of the TX constructs tested.
To quantitatively ascertain the effects of these barrier
structures on steady state substrate expression levels, the ex-
pression of vac-encoded full-length NP was assessed by NP-
specific immunoprecipitation of metabolically labeled vac-
infected cells. We found that the most thermostable of
these, HP20, reduced NP expression to undetectable levels
(
 
.
 
100-fold reduction) by this biochemical approach, while
HP18 reduced expression by 
 
z
 
100-fold. Interestingly, the
HP16 and HP14 structures showed similar decreases of ap-
proximately two- to fivefold (Fig. 6).
The panel of TX constructs was placed behind each of
these structures, recombined into vaccinia, and tested for
ACE-mediated presentation. We failed to see significant
presentation of any of the constructs when placed behind
HP20 and thus concentrated our analysis on the three less
stringent barrier hairpins. As shown in Fig. 7, presentation
efficiencies of the constructs across the range of barriers
were consistent with the biochemical and anti-CD8 analy-
Figure 4. Kinetics of purified ACE modification of synthetic substrates.
10 ng synthetic peptide was coincubated with ACE (0.001 U) for the in-
dicated times. Samples were then subjected to reverse-phase HPLC. Re-
action rates were monitored by the disappearance of the peak correspond-
ing to starting substrate.
Figure 5. ACE-rescued presentation under conditions of limited T cell
receptor stimulation. L-Kd cells were coinfected for 4 h with 5 PFU of
the indicated vac alone and 5 PFU ACE vac. 51Cr-labeled target cells
were then assessed for recognition by NP147–155-specific CTLs with or
without the indicated concentrations of anti-CD8 antibody 2.43. CTLs
were used at a constant effector/target ratio of 10:1.
Figure 6. Effect of a panel of thermostable duplex barriers on NP ex-
pression. (A) Schematic diagram of the hairpin structures. Arrows indicate
the sites of mismatched bps. (B) L-Kd cells were infected for 1 h with 10
PFU of the indicated vacs, followed by an additional 5 h in the presence
of [35S]methionine. Cells were lysed and protein A–Sepharose–cleared ly-
sates were subjected to immunoprecipitation by NP-specific antibodies. 
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ses. For example, the well-transported constructs, TM and
TL, sensitized targets suboptimally when placed behind
both the HP18 and the HP16 barriers. Both achieved opti-
mal presentation when placed behind HP14, the least ther-
mostable of the hairpin structures. TP, a poorly transported
substrate in vitro, exhibited significantly lower presentation
levels in all of the hairpin contexts. In experiment 2, pre-
sentation was still suboptimal in the HP14 context. Presen-
tation of the substrate exhibiting no detectable transport in
vitro, TG, was significantly lower in all contexts; presenta-
tion was still significantly suboptimal when placed behind
HP14. In fact, in the experiments shown, even wild-type
TG presentation was somewhat lower than the other con-
structs, although this was not consistently observed (see Fig. 2).
 
Discussion
 
We have used ACE-mediated processing in the exocytic
compartment, followed by recognition of the processed
peptide by CTLs, as a way of gauging TAP function within
intact cells. Several endogenously expressed substrates dif-
fering only at the COOH-terminal residues were generated
and their presentation efficiencies were compared to the
transport capabilities of synthetic correlates. This approach
allowed comparison of substrates that differed in transport
capability but all contained the same epitope. The analysis
was confined to substrates that could be modified by ACE
with similar kinetics. This eliminated differences in pro-
cessing, MHC binding, or T cell recognition as confound-
ing factors.
We found that TAP selectivity within the intact cell can
strongly influence T cell responses and that, at least with
regard to the contribution of the COOH-terminal residue,
this selectivity follows previously established rules. How-
ever, the in vitro assays do not entirely predict the effects of
transport selectivity. 147-155, TG, and TE (reference 14
and data not shown), despite exhibiting no detectable trans-
port in vitro, can sensitize target cells for CTL lysis. Whether
this is due entirely to the exquisite sensitivity of T cells, or
reflects the presence in the intact cell of factors that enhance
transport efficiency, is not known.
It will be of interest to determine whether established
biochemical results consistently predict effects of TAP
specificity upon T cell responses. Basic and acidic residues
at the COOH terminus, as well as proline and glycine,
studied in this paper, have been shown to have strong neg-
ative effects upon transport in vitro (15, 16). However, as
shown in Fig. 4, we were unable to evaluate glutamic acid
due to slower modification of TE by ACE. It may be that
our approach is not feasible for this group of amino acids.
Identity of internal residues and peptide length are also
strong determinants of in vitro transport efficiency. Investi-
gation of the internal residues using the system described
here would likely be challenging. First, changes within the
epitope itself will alter T cell responses, either by modifying
binding to class I or altering contact with T cell receptor,
limiting the number of possible internal changes. Second,
the assay depends upon the absence of antigen processing in
the cytosol and precise processing by a coexpressed pro-
tease after transport. With increasing peptide length, these
conditions may be difficult to achieve.
A subtle reduction in the amount of starting substrate, as
small as a twofold reduction in TX minigene expression
levels, allowed for discernment of the effects of TAP selec-
tivity. This is of particular importance given the findings of
Antón et al. (31) that endogenous expression of the NP
 
147–155
 
minigene results in a 1,000-fold greater number of epitopes
produced than when full-length NP is the starting sub-
strate. This is presumably due to more molecules being
synthesized in a given time frame and to a lack of the re-
quirement for processing in the cytosol. We assume that
expression of the TX minigenes gives rise to roughly the
same peptide numbers as the minigene-encoded minimal
epitope. If this is true, then the least stringent hairpin, HP14,
where expression levels are reduced only 2-fold, may still
give rise to substrate levels 
 
z
 
500-fold greater than those
normally seen after cytosolic generation of transportable
peptides from full-length NP. Yet TAP selectivity is clearly
evident in this case, becoming even more so when sub-
strate levels dip to z10-fold more than what would be pre-
dicted for full-length NP. This suggests that in the physio-
logic situation, where antigen is cytosolically processed
before transport, TAP preferences can be a powerful influ-
ence on the T cell response. Similarly, by using as little as a
100-fold less anti-CD8 antibody than is required to com-
pletely block T cell receptor–ligand interactions, one can
discern differences between well- and poorly transported
substrates. This suggests that TAP selectivity may allow for
qualitatively different responses of low versus high affinity
T cells.
Many investigators have questioned the adaptive value of
limiting the array of epitopes that can access the exocytic
compartment and become available for class I–restricted T
cell recognition. It has been suggested that restrictions im-
posed by TAP specificity may represent a balance between
the need to generate a variety of epitopes and the necessity
of preventing excessive clonal deletion during the process
of negative selection in the thymus (35). Alternatively, se-
lectivity has been proposed to enhance efficiency of the
processing pathway by minimizing the need to cycle non–
Figure 7. ACE-mediated rescue under conditions of limited starting
substrate. L-Kd cells were coinfected for 4 h with 5 PFU of the indicated
vacs alone and 5 PFU ACE vac. 51Cr-labeled target cells were then assessed
for recognition by NP147–155-specific CTLs. Shown are two independent
experiments. Effector/target ratios were 30:1 for experiment 1 and 28:1
for experiment 2.1661 Yellen-Shaw et al.
MHC-binding fragments back into the cytosol for further
destruction (36). To experimentally explore such questions,
it is critical that we employ assay methods that can most
finely discriminate the influences of such processes on T
cell recognition.
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